Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
7.87
-0.12 (-1.50%)
At close: May 22, 2026, 4:00 PM EDT
7.94
+0.07 (0.89%)
After-hours: May 22, 2026, 7:32 PM EDT
Artiva Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
104
Market Cap
382.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 251.00K | -33.24M | -99.25% |
| Dec 31, 2023 | 33.49M | 28.56M | 579.21% |
| Dec 31, 2022 | 4.93M | 2.93M | 146.30% |
| Dec 31, 2021 | 2.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 217.78M |
| Verastem | 49.59M |
| C4 Therapeutics | 34.86M |
| OmniAb | 28.94M |
| X4 Pharmaceuticals | 9.01M |
| Compass Therapeutics | 850.00K |
| InflaRx | 33.82K |
ARTV News
- 5 days ago - Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases - GlobeNewsWire
- 5 days ago - Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development - GlobeNewsWire
- 12 days ago - Artiva Biotherapeutics price target raised to $41 from $18 at Needham - TheFly
- 13 days ago - Artiva Biotherapeutics price target raised to $40 from $23 at Wedbush - TheFly
- 16 days ago - Artiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright - TheFly
- 16 days ago - Artiva Biotherapeutics Earnings release: Q1 2026 - Filings
- 16 days ago - Artiva Biotherapeutics Quarterly report: Q1 2026 - Filings
- 16 days ago - Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c) - TheFly